QQ客服 官方微博 反馈留言

	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
	Price, Timothy J.; Peeters, Marc; Kim, Tae Won; Li, Jin; Cascinu, Stefano; Ruff, Paul; Suresh, Atilli Satya; Thomas, Anne; Tjulandin, Sergei; Zhang, Kathy
刊名	LANCET ONCOLOGY
	2014
卷号	15期号:6
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4889048
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Price, Timothy J.,Peeters, Marc,Kim, Tae Won,et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study[J]. LANCET ONCOLOGY,2014,15(6).
APA	Price, Timothy J..,Peeters, Marc.,Kim, Tae Won.,Li, Jin.,Cascinu, Stefano.,...&Sidhu, Roger.(2014).Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.LANCET ONCOLOGY,15(6).
MLA	Price, Timothy J.,et al."Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study".LANCET ONCOLOGY 15.6(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。